Pharmaceutical composition for preventing cardiovascular diseases

A composition and drug technology, applied in the field of pharmacy, can solve the problem of weak cyclooxygenase effect, etc., and achieve the effects of preventing and treating atherosclerosis and inhibiting platelet aggregation.

Inactive Publication Date: 2017-01-11
SHENZHEN AUSA PHARM CO LTD +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, aspirin has a weak effect on the cyclooxygenase of vascular endothelial cells, and has a weak effect on prostacyclin I 2 (PGI 2 ) has little effect on the generation of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing cardiovascular diseases
  • Pharmaceutical composition for preventing cardiovascular diseases
  • Pharmaceutical composition for preventing cardiovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Preparation of compound atorvastatin / propranolol / aspirin / folic acid tablets

[0060] The prescription is as follows (1000 tablets):

[0061] Atorvastatin 10g

[0062] Propranolol 10g

[0063] Aspirin 75g

[0064] Folic acid 0.4g

[0065] Sodium Carboxymethyl Starch 20g

[0066] Calcium hydrogen phosphate 170g

[0067] 10% povidone aqueous solution appropriate amount

[0068] Magnesium Stearate 1%

[0069] Preparation method: pulverize the raw and auxiliary materials through an 80-mesh sieve, and dry for use. Take 10 g of atorvastatin, 10 g of propranolol, 75 g of aspirin and 0.4 g of folic acid and mix them uniformly according to the equal increment method, add 20 g of sodium carboxymethyl starch and 170 g of calcium hydrogen phosphate, and mix them evenly according to the equal increment method, and the folic acid Dissolve in 10% povidone aqueous solution of binder, add an appropriate amount of binder to make soft material, granulate with 30 mesh, dr...

Embodiment 2

[0070] Example 2: Preparation of compound tablets

[0071] Preparation method: same as Example 1.

[0072] The components and contents of the 14 kinds of compound recipes are shown in Table 11.

[0073] Table 1 Composition of 15 kinds of active compound medicines

[0074]

Embodiment 3

[0075] Example 3: Preparation of compound atorvastatin / enalapril / aspirin / folic acid capsules

[0076] The prescription is as follows (1000 capsules):

[0077]

[0078]

[0079] Preparation method: pulverize the raw and auxiliary materials through an 80-mesh sieve, and dry for use. Take 10g of atorvastatin, 20g of enalapril, 75g of aspirin and 0.4g of folic acid and mix them uniformly according to the equal increment method. ), uniformly mix according to the equal increment method, make soft material with 10% povidone ethanol solution, granulate with 20 mesh sieve, dry at 60°C for about 2 hours, granulate with 20 mesh sieve, and control the water content of the granules to be 2-3 %, the dried granules are uniformly mixed with the prescription amount of magnesium stearate, the semi-finished product is tested, the content is measured, and then packed into hollow capsules to obtain 1000 capsules. Avoid light during preparation. After the finished product has passed the in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a synergistic antihypertensive lipid-lowering pharmaceutical composition and the use of the pharmaceutical composition. The pharmaceutical composition comprises a pharmaceutical dosage of one of HMG-CoA reductase inhibitors, a pharmaceutical dosage of one of antihypertensive drugs, aspirin, folic acid and 5-methylaretetrahydrofolate, and a pharmaceutically acceptable carrier. The indication is hypertension accompanied with hyperlipidemia. The pharmaceutical composition can also be used as a primary drug for prevention of cardiovascular diseases. By the implementation of the invention, the pharmaceutical composition for the specific use for patients can improve the compliance of the patients, facilitate administration of the patients and reduce medical expenses, so that the pharmaceutical composition has relatively good market prospects.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing antihypertensive drugs, hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, aspirin and folic acid and its application. The present invention belongs to the field of pharmacy. Background technique [0002] Cardiovascular disease is one of the leading causes of human death, including coronary heart disease (myocardial infarction) and stroke (commonly known as stroke). The morbidity and mortality of cardiovascular disease in my country have been on the rise in the past 20 years, and the important reason is that the risk factors are increasing. These risk factors include hypertension, dyslipidemia, atherosclerosis, smoking, and alcohol consumption. Therefore, taking effective interventions to reduce the harm of various controllable risk factors is the key to preventing the occurrence of cardiovascular disease events such as coronary heart disease and stroke. [0003] A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/616A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P13/12A61P27/02A61K31/519A61K31/40A61K31/4178A61K31/41A61K31/138A61K31/366
CPCA61K45/06A61K31/138A61K31/366A61K31/40A61K31/41A61K31/4178A61K31/519A61K31/616A61K2300/00
Inventor 王念徐希平于多张磊白洁
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap